GlassScriptPhysician profile
Luke C Nicholas
NPI 1467509620
$4,343.60
in general payments reported to CMS, 2019-2025
23 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.00 · 2020: $101 · 2021: $310 · 2022: $359 · 2023: $1,019 · 2024: $1,127 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,169.73 | 2022-2025 | |
| Abbvie INC. | $636.71 | 2019-2025 | |
| Janssen Biotech, INC. | $461.12 | 2020-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $422.12 | 2020-2025 | |
| Ucb, INC. | $249.01 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $220.55 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $183.84 | 2020-2025 | |
| Amgen INC. | $176.39 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $138.03 | 2023-2025 | Hadlima |
| Leo Pharma INC. | $132.14 | 2022-2025 | Adbry |
| Lilly USA, LLC | $99.99 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $86.47 | 2024-2025 | |
| Incyte Corporation | $85.75 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $74.19 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.74 | 2023-2024 | Spevigo, Cyltezo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $28.54 | 2024 | |
| Vyne Pharmaceuticals INC. | $24.71 | 2020 | |
| Mimedx Group, INC. | $20.58 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.39 | 2019 | |
| Organogenesis INC. | $17.18 | 2024 | |
| Dermavant Sciences, INC. | $13.44 | 2023 | Vtama |
| Biofrontera INC. | $12.18 | 2021 | |
| Almirall LLC | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.